A Study to Explore the Effect of Acid-reducing Agents
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Registration Number
- NCT04935112
- Lead Sponsor
- Mirati Therapeutics Inc.
- Brief Summary
A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center, open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- Body mass index between 18.0 and 32.0 kg/m2, inclusive.
- In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and/or check-in, as assessed by the investigator (or qualified designee).
- Females of childbearing potential will not be pregnant or lactating and must have a negative result on an approved pregnancy test at screening and check-in. Females of childbearing potential must agree to use contraception.
- Male subjects must agree to use contraception.
- Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
Key
Exclusion Criteria
- Significant history of clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, any components of the IMP, or other substance (not including seasonal allergies), unless approved by the investigator.
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications. (Uncomplicated appendectomy and hernia repair are allowed. Cholecystectomy is not allowed.)
- History of Gilbert's syndrome or suspicion of Gilbert's syndrome based on elevated total and indirect bilirubin (may be confirmed by repeat).
- Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to study drug administration on Day 1 of Period 1.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Group 1 Treatment B (sitravatinib and pantoprazole) Sitravatinib Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7 Group 2 Treatment D (sitravatinib and famotidine) Sitravatinib Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1 Group 2 Treatment C (sitravatinib only) Sitravatinib Period 1: A single oral dose of 100 mg sitravatinib on Day 1 Group 1 Treatment A (sitravatinib only) Sitravatinib Period 1: A single oral dose of 100 mg sitravatinib on Day 1 Group 1 Treatment B (sitravatinib and pantoprazole) Pantoprazole Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7 Group 2 Treatment D (sitravatinib and famotidine) Famotidine Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1
- Primary Outcome Measures
Name Time Method Pharmacokinetics - Cmax (sitravatinib) Up to Day 7 after dosing Maximum observed plasma concentration
Pharmacokinetics - AUClast (sitravatinib) Up to 72 hours after dosing Area under the curve from time zero to the last measured time point
Pharmacokinetics - AUC∞ (sitravatinib) Up to 72 hours after dosing Area under the plasma concentration-time curve from time zero extrapolated to infinity
- Secondary Outcome Measures
Name Time Method Adverse Events (AEs) Up to 9 weeks from screening Incidence and severity of AEs
Trial Locations
- Locations (1)
Covance Clinical Research Unit Inc.
🇺🇸Madison, Wisconsin, United States